1 459

Cited 4 times in

Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer

DC FieldValueLanguage
dc.contributor.author구교철-
dc.contributor.author김기홍-
dc.contributor.author나군호-
dc.contributor.author박상언-
dc.contributor.author양승철-
dc.contributor.author유한나-
dc.contributor.author정병하-
dc.contributor.author한경석-
dc.contributor.author홍성준-
dc.date.accessioned2015-12-28T11:18:05Z-
dc.date.available2015-12-28T11:18:05Z-
dc.date.issued2015-
dc.identifier.issn0022-5347-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/139145-
dc.description.abstractPURPOSE: We determined the prognostic impact of a synchronous second primary malignancy on overall survival in patients with metastatic prostate cancer. Identifying features that stratify the risk of overall survival is critical for judiciously applying definitive therapy. MATERIALS AND METHODS: We retrospectively analyzed the records of 582 consecutive patients with prostate cancer diagnosed with metastasis between May 7, 1998 and August 27, 2011. Patient age, body mass index, ECOG performance status, Charlson comorbidity index, prostate specific antigen, T and N stages, Gleason and ASA® scores, progression to castration resistant prostate cancer, prior local treatments and synchronous second primary malignancies at metastasis were assessed. A synchronous second primary malignancy was defined as a cytologically or histologically proven solid malignancy. Cox proportional hazards regression analysis was done to estimate overall survival by second primary type and evaluate predictive variables. RESULTS: A total of 164 patients (28.1%) had a synchronous second primary malignancy, of which colorectal (9.1%), stomach (7.3%) and lung (7.1%) cancers were the most prevalent types. During a median followup of 34.1 months patients without a synchronous second primary malignancy had a significantly higher overall survival rate than those with lung or stomach cancer. However, men without a second malignancy had outcomes comparable to those in men with colorectal cancer. Clinical stage T4 or greater, ASA score 1 or greater and lung or stomach cancer were independent predictors of overall mortality. CONCLUSIONS: A substantial proportion of patients with metastatic prostate cancer present with a synchronous second primary malignancy. Definitive therapy targeting prostate cancer may confer a limited survival benefit in patients with synchronous lung or stomach cancer.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1239~1244-
dc.relation.isPartOfJOURNAL OF UROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasms, Second Primary/mortality*-
dc.subject.MESHPrognosis-
dc.subject.MESHProstatic Neoplasms/mortality*-
dc.subject.MESHProstatic Neoplasms/pathology*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk-
dc.subject.MESHSurvival Rate-
dc.titlePrognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨기과학)-
dc.contributor.googleauthorKyo Chul Koo-
dc.contributor.googleauthorHanna Yoo-
dc.contributor.googleauthorByung Ha Chung-
dc.contributor.googleauthorSeung Choul Yang-
dc.contributor.googleauthorSung Joon Hong-
dc.contributor.googleauthorKoon Ho Rha-
dc.contributor.googleauthorKyung Seok Han-
dc.contributor.googleauthorSang Un Park-
dc.contributor.googleauthorKi Hong Kim-
dc.identifier.doi10.1016/j.juro.2014.10.088-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00188-
dc.contributor.localIdA00343-
dc.contributor.localIdA01227-
dc.contributor.localIdA01486-
dc.contributor.localIdA02294-
dc.contributor.localIdA02529-
dc.contributor.localIdA03607-
dc.contributor.localIdA04264-
dc.contributor.localIdA04402-
dc.relation.journalcodeJ01921-
dc.identifier.eissn1527-3792-
dc.identifier.pmid25444987-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0022534714047697-
dc.subject.keywordmortality-
dc.subject.keywordmultiple primary-
dc.subject.keywordneoplasm metastasis-
dc.subject.keywordneoplasms-
dc.subject.keywordprognosis-
dc.subject.keywordprostatic neopla는-
dc.contributor.alternativeNameKoo, Kyo Chul-
dc.contributor.alternativeNameKim, Ki Hong-
dc.contributor.alternativeNameRha, Koon Ho-
dc.contributor.alternativeNamePark, Sang Un-
dc.contributor.alternativeNameYang, Seung Choul-
dc.contributor.alternativeNameYoo, Han Na-
dc.contributor.alternativeNameChung, Byung Ha-
dc.contributor.alternativeNameHan, Kyung Seok-
dc.contributor.alternativeNameHong, Sung Joon-
dc.contributor.affiliatedAuthorKoo, Kyo Chul-
dc.contributor.affiliatedAuthorKim, Ki Hong-
dc.contributor.affiliatedAuthorRha, Koon Ho-
dc.contributor.affiliatedAuthorPark, Sang Un-
dc.contributor.affiliatedAuthorYang, Seung Choul-
dc.contributor.affiliatedAuthorYoo, Han Na-
dc.contributor.affiliatedAuthorChung, Byung Ha-
dc.contributor.affiliatedAuthorHan, Kyung Seok-
dc.contributor.affiliatedAuthorHong, Sung Joon-
dc.rights.accessRightsfree-
dc.citation.volume193-
dc.citation.number4-
dc.citation.startPage1239-
dc.citation.endPage1244-
dc.identifier.bibliographicCitationJOURNAL OF UROLOGY, Vol.193(4) : 1239-1244, 2015-
dc.identifier.rimsid43802-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.